Nasdaq:US$32.17 (+0.00) | HKEX:HK$50.40 (+0.75) | AIM:£4.71 (+0.02)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
Careers
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
Careers
News & Presentations
Chi-Med
News & Presentations
| Presentations
Previous Article
|
Next Article
Presentations
,
Scientific Publications
| 14 Oct 2012
ISSX 2012: Pharmacokinetic/Pharmacodynamic Modeling of Epitinib to Evaluate the Anti-cancer Effect on A431 Tumor Xenograft in Nude Mice
1 items
View Poster (JPG)